TrialBrain communications2025
Phase 2 study of palmitoylethanolamide combined with luteoline in frontotemporal dementia patients.
Martina Assogna et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
5 papers cite it
this papercites it